Clinical Trial Update: Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating neoadjuvant lenvatinib combined with letrozole for hormone receptor-positive breast cancer; the study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• LENVIMA (lenvatinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING